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Abstract
Background: Type I interferons (IFNs) exhibit direct antiviral effects, but also distinct immunomodulatory
properties. In this study, we analyzed type I IFN subtypes for their effect on prophylactic adenovirus-based anti-
retroviral vaccination of mice against Friend retrovirus (FV) or HIV.
Results: Mice were vaccinated with adenoviral vectors encoding FV Env and Gag proteins alone or in combination
with vectors encoding IFNa1, IFNa2, IFNa4, IFNa5, IFNa6, IFNa9 or IFNb. Only the co-administration of adenoviral
vectors encoding IFNa2, IFNa4, IFNa6 and IFNa9 resulted in strongly improved immune protection of vaccinated
mice from subsequent FV challenge infection with high control over FV-induced splenomegaly and reduced viral
loads. The level of protection correlated with augmented virus-specific CD4
+ T cell responses and enhanced
antibody titers. Similar results were obtained when mice were vaccinated against HIV with adenoviral vectors
encoding HIV Env and Gag-Pol in combination with various type I IFN encoding vectors. Here mainly CD4
+ T cell
responses were enhanced by IFNa subtypes.
Conclusions: Our results indicate that certain IFNa subtypes have the potential to improve the protective effect of
adenovirus-based vaccines against retroviruses. This correlated with augmented virus-specific CD4
+ T cell and
antibody responses. Thus, co-expression of select type I IFNs may be a valuable tool for the development of anti-
retroviral vaccines.
Keywords: Friend virus, interferon alpha subtypes, human adenovirus vectors, human immunodeficiency virus,
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Background
Type I interferons (IFNs) are major players of the innate
immune response, which are produced by virus-infected
cells and plasmacytoid dendritic cells. The murine genome
comprises 14 type I IFN genes that encode structurally
similar proteins of 161-167 amino acids in length. Type I
IFN stimulation of a cell results in the expression of hun-
dreds of IFN-regulated genes that mediate an anti-viral
state of the cell [1]. In addition, type I IFNs also modulate
adaptive immune responses by activating antigen-present-
ing cells, promoting natural killer cell cytotoxicity and
enhancing the proliferation of CD4
+ and CD8
+ T cells [1].
All type I IFNs bind to and signal through the same recep-
tor IFNAR (IFNa receptor) that consists of the two
subunits IFNAR1 and IFNAR2; yet the anti-viral and
immunomodulatory effects mediated by individual type I
IFN subtypes vary considerably [2,3]. Distinct anti-viral
effects of IFN subtypes were demonstrated in several
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herpes simplex virus, influenza virus and Friend retrovirus
infection [4-9].
While the antiviral functions of type I IFNs have been
elucidated in detail, and IFN combination therapy is the
standard of care in some viral infections like chronic
hepatitis B and hepatitis C virus infection [10,11], their
potential for modulating adaptive immune responses has
only come into focus in recent years. Differing proper-
ties of distinct type I IFN subtypes have been described
for immunotherapeutic approaches, but have not been
systematically characterized for their effects on prophy-
lactic vaccines. In the work presented here, we aimed to
analyze type I IFN subtypes for their respective modu-
lating effect on anti-retroviral immunization.
Even after 25 years of intensive research, an effective
HIV vaccine remains elusive. Up to now, innumerable
vaccine candidates have been developed and evaluated in
preclinical models, but only three vaccines have been
advanced into efficacy testing in large phase IIB or phase
III clinical trials. The vaccination with a protein-based
vaccine or adenoviral vectors, aiming exclusively at the
induction of antibody responses or cytotoxic T cell
responses, respectively, did not result in any protective
effect [12,13]. Recently, the vaccination of a community-
risk group with a prime-boost combination of protein-
and canarypox vector-based vaccines conferred moderate
protection and instilled new hope in the field [14]. This
data, together with results from animal models [15,16],
indicate that for the prevention of HIV infection, both
cellular and humoral responses are necessary, and show
that it is mandatory to develop means to selectively
enhance these responses.
To analyze the protective effect of type I IFN subtypes
on adenovirus-based immunization, we employed the
Friend virus (FV) model. FV is an immunosuppressive ret-
rovirus complex of the non-pathogenic Friend murine leu-
kemia virus (F-MuLV) and the pathogenic, replication-
defective spleen focus forming virus (SFFV). FV infection
of susceptible adult mice induces splenomegaly and
erythroleukemia and takes a lethal course within a few
weeks [17]. The FV infection is regarded as a very useful
model for the analysis of immune responses to retroviral
infections and for the identification of mechanisms of pro-
tection. It was shown that complete immune protection
from FV infection requires complex immune responses
involving antibodies and CD4
+ as well as CD8
+ Tc e l l s
[15]. Previously, we demonstrated that the FV model is
very suitable for the development and assessment of novel
vectors and strategies for anti-retroviral vaccination. In
this model, we showed the benefit of heterologous adeno-
virus-based prime-boost immunization, which resulted in
better protection from FV challenge and enhanced neutra-
lizing antibody responses than the repeated administration
of one vector type [18]. Furthermore, we developed a new
type of adenovirus-based expression-display vector that
not only encodes a transgene, but also presents it on the
adenovirus capsid and conferred strong protection from
FV challenge infection, correlating with augmented CD4
+
T cell and anamnestic neutralizing antibody responses
[19].
Using adenoviral vectors encoding F-MuLV Env and
Gag proteins co-administered with vectors encoding
murine type I IFN subtypes, we aimed to elucidate the
effects of particular subtypes on vaccine-mediated pro-
tection in the FV model. To verify the results obtained in
the FV model, we also performed immunizations of mice
with adenoviral vectors expressing HIV Env and Gag-Pol
proteins with co-administration of vectors encoding type
I IFN subtypes.
Results
Enhanced FV immune protection after co-administration
of adenoviral vectors expressing FV proteins and specific
type I IFN subtypes
We generated E1-, E3-deleted Ad5-based vectors with
wild-type or chimeric Ad5/35 fiber encoding murine type
I IFN subtypes IFNa1, IFNa2, IFNa4, IFNa5, IFNa6,
IFNa9o rI F N b. The identities of the IFN subtypes were
verified by sequencing. and similar expression levels and
biological functionality were demonstrated in an estab-
lished bioassay [20] (data not shown). F-MuLV Env
and Gag encoding adenoviral vectors were described
previously [18].
Highly FV-susceptible CB6F1 mice were immunized
with 1 × 10
9 viral particles (VP) each of F-MuLV Env-
and Gag-encoding Ad5 vectors and boosted with the
same dose of Ad5F35 vectors three weeks later (see Addi-
tional file 1, Figure S1 for a schematic outline of the
experiment). In contrast to our previous work in which
we immunized with 5 × 10
9 VP of each vector (1 × 10
10
VP total dose) [18,19], this reduced-dose immunization
was chosen because it induces only moderate protection
on its own, enabling us to analyze the beneficial effect
of vectored type I IFN co-administration on vaccine pro-
tection. Mice received the adenovirus-vectored F-MuLV
antigens co-administered with vectors encoding
the selected type I IFN subtypes described above; as a
control, one group of mice received the adenoviral
vectors encoding F-MuLV Env and Gag and were co-
administered vectors encoding luciferase as an irrelevant
transgene in order to administer equal amounts of ade-
noviral particles to all mice. Three weeks after the boost
immunization the mice were challenged with FV and
the spleen size as a surrogate marker for disease progres-
sion was monitored by abdominal palpation. While the
immunization of mice with the reduced dose of F-MuLV
Env- and Gag-encoding vectors alone did not result in
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administration of adenoviral vectors encoding IFNa2,
IFNa4, IFNa6 or IFNa9, but not IFNa1, IFNa5 or IFNb,
resulted in significant reduction of FV-induced spleno-
megaly (P < 0.05; shown in Figure 1A and 1B for days 14
and 17 post-challenge (p.c.)). Improved protection after
co-administration of the four IFN subtype vectors was
confirmed when animals were sacrificed and spleen
weights were measured on day 21 p.c. (Figure 1C). At
this time point, the spleen weights of all vaccinated mice
were significantly lower than of unvaccinated control
mice demonstrating a moderate protective effect of the
low-dose vaccination with F-MuLV Env- and Gag-encod-
ing Ad5 and fiber-chimeric Ad5F35 vectors. However,
protection against splenomegaly was significantly
improved when mice had been co-administered vectors
encoding IFNa2, IFNa4, IFNa6 or IFNa9( P < 0.05).
To ascertain that the observed effects of type I IFN co-
administration were due to a modulation of the immune
response to the vaccination and not to a direct antiviral
effect of residual IFN expression, mice were adminis-
tered type I IFN encoding vectors alone and challenged
afterwards with FV according to the same scheme. Here,
no differences in the control of FV-induced disease were
observed (Figure 1D).
Co-administration of specific type I IFN subtypes
mediated improved control over viral replication in
vaccinated mice
To determine whether co-administration of type I IFNs
resulted in improved control over virus replication after
FV challenge, viral loads in plasma of animals immunized
with F-MuLV Env and Gag encoding vectors with or with-
out co-administration of IFN subtype encoding vectors
were analyzed at 10 days after FV infection (Figure 2A).
Vaccination with Env- and Gag-encoding vectors alone
only slightly reduced acute viral loads but a significant
reduction in viral titers was found in animals after co-
administration of adenoviral vectors encoding the subtypes
IFNa4, IFNa6o rI F N a9( P <0 . 0 5 ) .S o m eo ft h em i c e
from these three groups even had viral loads below the
detection limit of the assay. Co-administration of vectored
IFNa2 also reduced the plasma viremia level of some mice
compared to F-MuLV Env and Gag vaccinated mice but
this reduction was not statistically significant.
In addition to acute viremia levels, numbers of infec-
tious cells in the spleens of vaccinated mice were deter-
mined 21 days p.c. (Figure 2B). Co-administration of
adenoviral vectors encoding IFNa2, IFNa4o rI F N a6
resulted in a significant reduction of spleen viral loads
compared to both unvaccinated mice or mice vaccinated
with Env- and Gag-encoding vectors alone (P < 0.05); the
reduction in mean spleen viral loads was more than
1000-fold. After co-administration of vectors encoding
IFNa9o rI F N b, the mean viral loads in spleens of mice
were also reduced more than 100-fold compared to
unvaccinated or Env- and Gag-vaccinated mice, but the
differences did not reach statistical significance (P >
0.05). No adjuvant effect on vaccine protection against
FV was found for IFNa1 and IFNa5.
IFNa2, 4, 6 and 9 co-expression enhanced vaccine-
induced CD4
+ T cell responses
To elucidate the immunological mechanisms leading to
improved protection after co-administration of specific
type I IFN subtypes, we analyzed the virus-specific T cell
response in mice vaccinated either with Env- and Gag-
encoding vectors alone or in combination with vectors
encoding the four subtypes that improved protection
(IFNa2, IFNa4, IFNa6o rI F N a9). Mice were vaccinated
and challenged as described before and class I and II tet-
ramer staining was performed at 3 days p.c. to quantify T
cell responses (see Additional file 1, Figure S1 for a sche-
matic outline of the experiment). For FV, only one H2-
D
b-restricted CD8
+ T cell epitope, the GagL epitope [21],
has been identified so far. However, this epitope is not
processed in cells infected with the F-MuLV Gag-encod-
ing adenoviral vector used in this study (data not shown).
Therefore, it was not surprising that no FV-specific CD8
+
T cells were detected with class I tetramers in any of the
vaccinated mice (data not shown). In contrast, shortly
after FV challenge F-MuLV Env-specific CD4
+ T cells
could be quantified using MHC II tetramers presenting
an F-MuLV gp70 epitope [22]. No tetramer
+ CD4
+ T
cells were detectable in unvaccinated mice and in mice
vaccinated with Env and Gag alone (Figure 3). In con-
trast, virus-specific CD4
+ T cells were found in all mice
that were co-administered vectors encoding IFNa2,
IFNa4, IFNa6o rI F N a9 (with only one exception in the
IFNa9g r o u p ;P < 0.05; Figure 3A). Representative dot
plots are shown in Figure 3B. Thus, these particular IFN
subtypes significantly augmented FV-specific CD4
+ T cell
responses.
The role of T cells in IFN subtype mediated enhanced
vaccine protection
Previous work indicates that both CD4
+ and CD8
+ Tc e l l
responses contribute to vaccine protection against FV
[ 1 5 ] .H o w e v e r ,o n l yF V - s p e c i f i cC D 4
+ T cell responses
were detected in the current vaccine study. To elucidate
the impact of CD4
+ and CD8
+ T cells on vaccine-
mediated protection after co-administration of IFN sub-
types, T cell depletion experiments were performed (see
Additional file 1, Figure S1 for a schematic outline of the
experiment). IFNa4 co-administration was selected to
perform these experiments because it was the subtype
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Figure 1 FV-induced splenomegaly in adenoviral vector immunized mice. CB6F1 mice were immunized with Ad5 and Ad5F35 based
vectors encoding F-MuLV Env and Gag with or without co-administration of a specific vectored type I IFN subtype, as indicated. Ad5-based
vectors were used for the prime immunization and Ad5F35 vectors for the boost immunization. Mice of the group “env+gag” received an equal
amount of luciferase encoding adenoviral vectors instead of IFN encoding vectors to ensure that the total amount of particles used for
immunization was the same in all groups. Three weeks after the boost immunization mice were challenged with FV. Disease progression was
monitored by palpation of the spleen twice a week. The categorized spleens of six mice per group on day 14 p.c. (A) and day 17 p.c. (B) are
shown (means + standard error of the means). On day 21 p.c. spleens were removed and weighed (C). Statistically significant differences (P <
0.05) compared to unvaccinated control mice (*) or mice vaccinated with Env- plus Gag-encoding vectors (#) are indicated. Data are
representative of two independent experiments. (D) CB6F1 mice were immunized twice with Ad5 and Ad5F35 based vectors encoding the
indicated type I interferons alone and infected with FV three weeks after the second application of IFN vectors. The disease progression was
monitored by twice-weekly palpations of the spleen, the graph shows the categorized spleen sizes (mean + standard error of the means) at the
indicated time points after FV infection.
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vaccinated mice (Figure 2). Depletion of CD8
+ Tc e l l s
during the time of vaccination did not result in reduced
protection in mice inoculated with vectors encoding Env-
and Gag and IFNa4 (Figure 4). This indicates that in the
absence of CD8
+ T cells reactive to the immunodomi-
nant GagL epitope, also no CD8
+ T cells of other,
unknown specificity played a major role in vaccine-
mediated protection. However, depletion of CD4
+ T cells
had a profound effect on protection. The depletion abol-
ished the protective effect of the Env/Gag/IFNa4 vaccine
completely as indicated by severe splenomegaly (Figure
4A) and high plasma (Figure 4B) and spleen (Figure 4C)
viral loads in these mice. Thus, the CD4
+ T cell response
in Env and Gag vaccinated mice, which was augmented
by co-administration of IFNa4 (Figure 3) was absolutely
critical for vaccine protection.
To analyze the kinetics of the improved CD4
+ T cell
r e s p o n s e ,w ei m m u n i z e dm i c eo n c ew i t hA d 5 . e n v + g a g
or Ad5.env+gag+IFNa4 and analyzed activation of CD4
+
T cells in the draining lymph nodes at 3, 7 or 10 days
after immunization. While we did not see any difference
between mice from the two groups in the percentage of
activated CD4+ T cells with effector phenotype (CD43
+
CD44
+ CD62L
- CD4
+ T cells; data not shown), at 10
days after immunization the mean percentage of acti-
vated CD43
+ CD44
+ CD4
+ T cells with a entral memory
phenotype (CCR7
+ CD62L
+) was increased in mice co-
administered IFNa4 (Figure 4D), suggesting a role of
IFNa4 in CD4
+ T cell memory formation.
Enhanced antibody titers after co-administration of
specific type I IFN subtypes
Virus-specific antibodies have been shown to play an
important role in vaccine protection against FV infec-
tion [15,23]. Therefore, we analyzed the humoral
immune responses to vaccination at 18 days after the
boost immunization as well as 10 days p.c. After Env-
and Gag-vaccination, only two out of six mice had
developed detectable F-MuLV-binding antibodies after
the boost immunization (Figure 5A), whereas all mice
that had received vectors encoding IFNa2, IFNa4,
IFNa6o rI F N a9 had significantly higher mean F-
MuLV-binding antibody titers (P < 0.05), with the
highest titers found in mice that had been co-adminis-
tered vectors encoding IFNa2a n dI F N a9. FV neutra-
lizing antibodies were not detected in any of the
vaccinated mice (data not shown). However, at ten
days after FV challenge, most vaccinated animals
showed low titers of F-MuLV-neutralizing antibodies
(Figure 5B), which were only increased after co-admin-
istration of IFNa2- and IFNa4-encoding vectors com-
p a r e dt ot h eg r o u po fE n v -a n dG a g - i m m u n i z e dm i c e .
While this increase was statistically significant for
IFNa4( P < 0.05; Figure 5B), it did not reach statistical
significance for IFNa2.
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Figure 2 Viral loads after FV challenge infection of vaccinated mice. CB6F1 mice were prime- and boost-immunized with Ad5 and Ad5F35
based vectors, respectively, encoding F-MuLV Env and Gag with or without co-administration of a specific vectored type I IFN subtype, as
indicated. Three weeks after the boost immunization mice were challenged with FV. Viral loads in the plasma of FV-infected mice were analyzed
on day 10 p.c. (A) shows viremia levels as FFU/ml, median values are indicated by lines. On day 21 p.c. the viral loads in spleen were analyzed
(B), the graph shows the viral load as IC/spleen, the horizontal lines mark median values. Statistically significant differences (P < 0.05) compared
to unvaccinated control mice (*) or mice vaccinated with Env- plus Gag-encoding vectors (#) are indicated. Each dot represents an individual
mouse. Data are representative of two independent experiments with similar results.
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vaccine were improved by co-administration of select
type I IFN subtypes
To determine whether the adjuvant effect of type I IFN
subtypes also applied to vaccination against HIV, we ana-
lyzed immune responses to an HIV vaccine in mice using
adenoviral vectors expressing HIV Env and Gag-Pol
alone or in combination with vectors encoding IFNa2,
IFNa4, IFNa6o rI F N a9. For the analysis of cellular
immune responses, BALB/c mice were immunized once
with Ad5-based vectors and spleens were removed two
weeks later (see Additional file 1, Figure S1 for a sche-
matic outline of the experiment) to determine cytokine
production by CD4
+ and CD8
+ T cells after in vitro resti-
mulation with HIV Gag derived peptides that have been
described before to be relevant T cell epitopes in BALB/c
mice [24,25].
A significant induction of CD4
+ T cells producing IFNg,
TNFa or IL-2 by the HIV antigen encoding adenovirus-
based vaccine was observed in all mice (P < 0.05; Figure 6
A-C). Compared to Env- and Gag-Pol-immunization
alone, significantly higher mean percentages of HIV Gag-
specific CD4
+ T cells producing IL-2 (only for IFNa2) or
TNFa after restimulation were found in mice that had
been co-administered vectors encoding IFNa2, IFNa4o r
IFNa9( P < 0.05). In contrast, IFNa6 had no effect on
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Figure 3 Vaccine-induced F-MuLV Env-specific CD4
+ T cell responses. CB6F1 mice were prime- and boost-immunized with Ad5 and Ad5F35
based vectors, respectively, encoding F-MuLV Env and Gag with or without co-administration of a specific vectored type I IFN subtype, as
indicated. Three weeks after the boost immunization mice were challenged with FV and the F-MuLV Env-specific CD4
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+ T cells, the line designates the mean value. Statistically significant differences (P < 0.05) compared to unvaccinated
control mice (*) or mice vaccinated with Env- plus Gag-encoding vectors (#) are indicated. Each dot represents an individual mouse. Data are
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Figure 4 Depletion of CD4
+ and CD8
+ T cells during vaccination. CB6F1 mice were vaccinated with adenoviral vectors encoding F-MuLV
Env and Gag with or without co-administration of vectored IFNa4 as described before. On day -3, -1, +1, +3, and +5 of vaccination, mice were
injected i.p. with antibodies against CD4 or CD8 to deplete the respective T cell subset. After FV challenge infection, spleens were palpated
twice a week to monitor disease progression (A). Viral loads in plasma were determined on day 10 p.c. (B), viral loads in spleen were analyzed
on day 21 p.c. (C). For the analysis of T cell induction, mice were immunized once with the indicated vectors and the expression of CD43, CD44,
CD62L and CCR7 on CD4+ T cells in the draining lymph nodes was analyzed 10 days after immunization (D). The graphs show data of four mice
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+ T cell responses. In addition, the
IFNg expression by CD4
+ T cells was not changed by any
of the four type I IFN subtypes. Similar results were also
obtained when mice were immunized twice with a prime
boost immunization protocol using Ad5-based vectors for
priming and Ad5F35-based vectors for boosting, resem-
bling the FV experiments. Again IFNa2, IFNa4 or IFNa9
enhanced CD4
+ T cells responses but in these experiments
the differences between the groups were not as pro-
nounced as after only one vaccination (data not shown).
Similar to the CD4
+ T cell response, the HIV Env- and
Gag-Pol-immunization induced cytokine producing CD8
+
T cells, which responded specifically to restimulation with
Gag-derived peptides (Figure 6 D-E). The mean percen-
tages of cytokine producing CD8
+ T cells were higher
than those for CD4
+ T cells. However, after co-delivery of
IFNa2, IFNa4o rI F N a6 only slightly enhanced mean per-
centages of IL-2 producing HIV Gag-specific CD8
+ Tc e l l s
were detected than in Env- and Gag-Pol-immunized mice
and the difference did not reach statistical significance.
Expression levels of TNFa and IFNg were comparable in
all immunized mice irrespective of IFN co-administration,
with very high percentages of IFNg-producing CD8
+ T
cells in all groups. Similar results were obtained when
CD8
+ T cells were restimulated with an Env-derived epi-
tope peptide (data not shown).
These data underline the impact of specific type I IFNs
on vaccine-induced CD4
+ T cell responses, whereas only
little effect on the CD8
+ T cell response could be
demonstrated.
Discussion
Type I IFN subtypes have distinct immunomodulatory and
antiviral properties, which implies that they have different
potentials for immunotherapeutic applications [4-9] and
emphasizes the need for careful subtype selection for infec-
tious disease treatment. Type I IFNs have also been used
to improve the efficacy of experimental vaccines including
protein [26], DNA [8,27-30] and viral vector vaccines
[31-33], but a systematic approach to study the adjuvant
efficacy of different IFN subtypes has not been undertaken
so far. In this study, we analyzed seven adenovirus-vectored
type I IFN subtypes for their effect on an adenoviral vector-
based anti-retroviral vaccination. As expected, the effect on
vaccine efficacy of the IFN subtypes differed greatly. While
the co-administration of adenoviral vectors encoding
IFNa2, IFNa4, IFNa6 and IFNa9 led to improved control
over FV-induced disease and strongly reduced viral loads,
no or only slight effects were observed after co-administra-
tion of the subtypes IFNa1, IFNa5a n dI F N b. All four IFN
subtypes that improved vaccine protection enhanced virus-
specific CD4
+ T cell and antibody responses.
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+ T cell
response for vaccine protection was emphasized by a
depletion experiment, in which vaccine-mediated pro-
tection was completely abolished when CD4
+ T cells
were depleted around the time point of vaccination. The
kinetic analysis of the early activation of B cells and
CD4
+ T cells after vaccination suggests that co-adminis-
tration of IFNa4 might influence the CD4
+ memory T
cell formation, whereas no differences in overall activa-
tion of CD4
+ or CD8
+ T cells with effector phenotype
or B cells was found (data not shown). An improved
central memory CD4
+ T cell response might be critical
for enhanced virus-specific cellular and humoral recall
responses after virus challenge, as similar findings have
been reported for FV infected mice [34].
The importance of CD4
+ T cell responses for vaccine-
induced protection from FV infection has been demon-
strated before in mice vaccinated with an attenuated F-
MuLV and in vaccination studies with peptides containing
CD4
+ T cell epitopes [35,36]. In the attenuated vaccine
experiments it was suggested that the CD4
+ T cells mainly
provided help for B cells and CD8
+ T cells rather than
exerting direct effector functions [15,37]. It was also
shown in FV infected mice that the CD4
+ T cell response
is crucial for efficient induction of virus-specific antibodies
[34]. These findings correspond well with our data, as we
observed a correlation of CD4
+ T cell induction and anti-
body responses in mice vaccinated against FV.
The important role of antibodies for protection from
FV infection has also been demonstrated before [15,37].
It is noteworthy that in our challenge experiment, mice
that were co-administered IFNa4 had the strongest ana-
mnestic neutralizing antibody response and also the low-
est acute viral load in plasma. While this antibody
response might be influenced by the augmented CD4
+ T
cell response, a direct effect of the type I IFNs on anti-
body induction is conceivable, as it has been shown that
type I IFNs enhance primary antibody responses, pro-
mote isotype switching and can increase B cell survival
[38,39].
In mice immunized with peptides representing CD4
+ T
cell epitopes, improved maturation of neutralizing anti-
bodies [36], but also direct effector function of vaccine-
induced CD4
+ T cells have been reported [35]. Also in
FV-infected mice, direct anti-viral effects of CD4
+ T cells
have been documented [34,40,41], which were found to
be mediated by inhibition of virus replication by produc-
tion of IFNg and by MHC class II restricted cytotoxicity
[40]. Type I IFNs can promote expansion of CD4
+ T cells
either indirectly through effects on antigen-presenting
cells [42] or through direct action [43,44]. The current
findings suggest that co-delivery of certain type I IFN
subtypes in our vaccine may facilitate the induction of
direct anti-viral CD4
+ T cell activity. This is supported by
t h ef a c tt h a tw es e eas t r o n gc o r r e l a t i o no fh i g hc o n t r o l
of FV-induced disease with the augmented CD4
+ T cell
response, whereas the levels of binding and neutralizing
antibodies are not equally increased by co-administration
of all analyzed IFNs, indicating a direct function of virus-
specific CD4
+ T cells.
In the FV model, the only known CD8
+ T cell epitope
is located in the leader region of the Gag protein [21],
but after vaccination with adenoviral vectors encoding F-
MuLV Gag, no immune response against this epitope
was detected because the epitope peptide was obviously
not processed. However, the vaccination with adenoviral
vectors very likely induced CD8
+ T cell responses of up
to now unknown specificity as activated CD8
+ T cells
with effector phenotype were detected after immuniza-
tion (data not shown). This is in line with previous
reports that after vaccination with vaccinia viruses encod-
ing different F-MuLV Gag constructs also regions other
than the leader can induce protective CD8
+ T cell
immune responses [45]. However, our CD8
+ T cell deple-
tion experiment did not result in reduced protection,
suggesting that CD8
+ T cell responses against other epi-
topes did not play a critical role for the improved protec-
tion after co-administration of type I IFNs. Our data
from vaccination of mice against HIV proteins also
showed only minor effects of type I IFNs on CD8
+ Tc e l l
responses, suggesting that these cytokines may not be
very efficient to enhance adenovirus-based vaccine
induced CD8
+ T cell responses.
Some of the IFN subtypes used in this study have been
evaluated before to enhance immune responses to protein,
plasmid or viral vector based vaccines. The data imply that
the adjuvant potential of IFN subtypes may vary depend-
ing on the type of vaccine. For DNA and protein-based
vaccines against model antigens or virus infections, most
efforts to improve vaccine efficacy by co-administration of
type I IFNs resulted in improved antibody and CD8
+ T
cell responses that mediated enhanced protection
[8,26-30]. The effect of type I IFN co-expression in virus-
vector based vaccines, however, seems to depend on the
vector-type. Immune responses, but not protection,
induced by a rabies virus based vaccine against HIV could
be improved by co-expression of IFNb [32]. The protective
effect of a vaccinia virus-vectored vaccine against influ-
enza, on the other hand, was not improved by IFNb or
IFNa4 co-administration [31]. Interestingly, none of the
above cited publications reports an enhanced induction of
CD4
+ T cells, while we found strongly augmented CD4
+ T
cell responses that correlated well with the observed
improved protection against systemic FV challenge infec-
tion conferred by codaministration of specific type I IFN
subtypes with the vaccine.
It seems plausible that virus-based vectors are more
immunogenic by themselves and thus effects of cytokine
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protein vaccines. In our current vaccination study, the
finding that only IFNa2, IFNa4, IFNa6 and IFNa9, but
not IFNa1, IFNa5a n dI F N b, had an adjuvant effect on
the adenovirus-based vaccine may also be related to the
immunogenicity of the vector itself. In fact, the ineffec-
tive IFN subtypes were those that were expressed at the
highest levels in Ad-infected DCs (see Additional file 2,
Figure S2), which is in accordance with an earlier report
showing that the adenovirus-induced type I IFN
response was predominantly comprised of IFNa1,
IFNa5a n dI F N b [46]. While additional expression of
these IFN subtypes from the vaccine vectors did not
enhance immunogenicity, broadening the IFN profile by
expressing other IFN subtypes seems to be more effec-
tive. It has been established that, while all type I IFNs
signal through the same receptor, the IFN subtypes bind
this receptor with different affinities [47,48]. These dif-
ferences in receptor binding can result in different
downstream signaling events and distinct induction of
interferon stimulated genes. Thus, the tested IFN sub-
types may have induced different activation pattern in
vaccine-primed immune cells, which might be an under-
lying mechanism for their distinct adjuvant effects.
The homology between murine and human type I
interferons is rather low with about 70-75% at the
nucleotide level [49], so a direct translation of our find-
ings into HIV vaccine development for humans is diffi-
cult. However, also human type I interferon subtypes
exhibit distinct immunological functions [47], so that
our main findings that different IFN subtypes have dis-
tinct potencies as vaccine adjuvants should hold true for
human IFN subtypes as well. Thus, human IFN subtypes
should be tested when developing HIV prototype
vaccines.
We demonstrated that the protective effect of low-dose
immunization against retroviruses with adenoviral vec-
tors could be highly improved by co-administration of
specific vectored type I IFN subtypes, which induced
strong CD4
+ T cell responses and enhanced binding anti-
body titers. This shows that careful manipulation of the
cytokine milieu can result in impressive advancement in
vaccine efficacy and suggests that IFN subtypes may be
useful tools to improve immune responses to adenovirus-
based vaccines.
Conclusions
This study examines the adjuvant effect of distinct type I
IFN subtypes on an adenoviral vector-based anti-retroviral
vaccine. In the Friend virus model, the co-delivery of
IFNa2, IFNa4, IFNa6 and IFNa9 together with viral anti-
gens by an adenovirus-based vaccine resulted in strong
improvement of vaccine efficacy that was apparent by high
control over FV-induced disease and correlated with
improved CD4
+ T cell responses and higher binding anti-
body titers. Similar findings were made when mice were
immunized with adenovirus-based vectors encoding HIV
proteins. No influence on vaccine efficacy was observed
for co-administration of vectored IFNa1, IFNa5a n d
IFNb. Our results show that co-expression of specific type
I IFN subtypes should be considered for adenovirus-based
anti-retroviral vaccination.
Methods
Cells and cell culture
The human embryonic kidney cell line 293 (Microbix Bio-
systems, Toronto, ON, Canada), the human lung carci-
noma cell line A549 (ATCC # CCL-185) and the type I
IFN indicator cell line MxRAGE7 ([20], Werner Müller,
German Research Centre for Biotechnology, Braunsch-
weig, Germany) were propagated in Dulbecco’s modified
Eagle medium (DMEM) with high glucose. A murine
fibroblast cell line from Mus dunni [50] was maintained in
RPMI medium (Invitrogen/Gibco, Karlsruhe, Germany).
Cell culture media were supplemented with 10% heat-
inactivated fetal bovine serum (Invitrogen/Gibco) and
50 μg/ml gentamicin. Cell lines were maintained in a
humidified 5% CO2 atmosphere at 37°C (293, M. dunni)
or 32°C (MxRAGE7).
Adenoviral vectors
The adenoviral vectors Ad5.env, Ad5F35.env, Ad5.gag,
and Ad5F35.gag [18] encode full-length F-MuLV Env or
Gag proteins amplified by PCR from F-MuLV clone
FB29 [51]; vectors were obtained using the AdEasy sys-
tem and vectors pAdTrackCMV, pAdEasy-1, and
pAdEasy-1/F35.
The adenoviral vector Ad5.Henv contains a codon-opti-
mized full-length env based on HIV clade C isolate CN54
and was obtained using the AdEasy system after cloning of
synthesized DNA into pShuttle-CMV plasmid. Ad5.
Hgpsyn contains a codon-optimized HIV gag-pol based on
the HIV clade B isolate BH10 that was described before
[52] and was constructed using the AdEasy system and
vectors pShuttle-CMV and pAdEasy-1.
The adenoviral vectors Ad5.Luc and Ad5F35.Luc
encoding firefly luciferase have been described before
[53,54].
For the construction of type I IFN encoding adenoviral
vectors, cDNAs for IFNa1, IFNa2, IFNa4, IFNa5,
IFNa6, IFNa9a n dI F N b were subcloned from the plas-
mids pkCMVint.IFNa1, pkCMVint.IFNa2, pkCMVint.
IFNa4, pkCMVint.IFNa5, pkCMVint.IFNa6, pkCMVint.
IFNa9 [4] and pkCMVint.IFNb [5] into pShuttle, recom-
binant Ad5 and Ad5F35 based vectors were obtained by
homologous recombination of pShuttle constructs with
pAdEasy-1 and pAdEasy-1/F35, respectively, and trans-
fection into 293 cells as described before [18].
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AdenoPACK 100 kit (Vivascience, Hannover, Germany).
The adenovirus particle concentrations were determined
by spectrophotometry as described previously [55] and
expressed as viral particles (VP)/ml. The particle-to-PFU
ratio of all vector preparations was ~30:1.
Equal expression levels of IFNs by the recombinant
adenovirus constructs were verified by a cell based bioas-
say using MxRAGE7 cells as described before [20].
Briefly, non-complementing A549 cells were transduced
with type I IFN encoding adenoviral vectors at an MOI
of 100, culture supernatants were collected three days p.i.
a n da d d e dt os u b c o n f l u e n tM x R A G E 7c e l l st h a tw e r e
incubated for 2 days at 37°C. Type I IFN induced GFP
expression was analyzed by flow-cytometry.
Mice
Female CB6F1 hybrid mice (BALB/c × C57BL/6 F1; H-
2
b/d Fv1
b/b Fv2
r/s Rfv3
r/s)a n df e m a l eB A L B / cm i c ew e r e
purchased from Charles River Laboratories (Sulzfeld,
Germany). All mice were used when they were between 8
and 9 weeks of age and were treated in accordance with
the regulations and guidelines of the institutional animal
care and use committee of the Ruhr University Bochum,
Germany.
Immunization
For immunization against FV, CB6F1 mice were immu-
n i z e dw i t hA d 5a n dA d 5 F 3 5 - b a s e dv e c t o r su s i n gah e t -
erologous prime-boost immunization protocol with a
21-day interval. 1 × 10
9 VP each of F-MuLV Env- and
Gag-encoding vectors were mixed with either 1 × 10
9
VP of a type I IFN-encoding vector or a luciferase-
encoding vector as a control and injected into both hind
footpads in 100 μl PBS. Ad5 vectors were used for the
prime immunizations, and fiber-chimeric Ad5F35 vec-
tors were used for boost immunizations.
In a control experiment, CB6F1 mice were immunized
as described above with 1 × 10
9 VP of type I IFN-
encoding vectors alone, using Ad5 vectors for prime and
Ad5F35 vectors as boost immunizations.
To deplete CD4
+ or CD8
+ cells around the time of vac-
cination, mice were injected intraperitoneally with the
antibodies 191.1 or 169.4 [56], respectively, on days -3, -1,
+1, +3, and +5 around the day when the vaccine was
applied. The depletion was performed when mice were
prime- and boost-immunized.
For immunization against HIV, BALB/c mice were
vaccinated with a single or a prime-boost immunization
with Ad5-based vectors encoding HIV Env and Gag-Pol
mixed with type I IFN- or luciferase-encoding vectors as
described for vaccination against FV. When mice were
boost immunized, Ad5-based HIV Env- and Gag-Pol-
encoding vectors and Ad5F35-based type I IFN- or luci-
ferase-encoding vectors were used.
FV and challenge infection
Uncloned, lactate dehydrogenase-elevating virus (LDV)-
free FV stock was obtained from BALB/c mouse spleen
cell homogenate (10%, wt/vol) 14 days p.i. with a B-cell-
tropic, polycythemia-inducing FV complex [57]. CB6F1
mice were challenged by the intravenous injection of
250 spleen focus-forming units. The course of disease
was monitored twice a week by palpation of the spleen
of each animal under general anesthesia. The spleen size
was rated on a scale ranging from 1 (normal spleen
size) to 4 (severe splenomegaly), as described previously
[58].
Viremia assay
Ten days post challenge (p.c.), plasma samples from
CB6F1 mice were obtained, and viremia was determined
in a focal infectivity assay [59]. Serial dilutions of plasma
were incubated with M. dunni cells for 3 days under
standard tissue culture conditions. When cells reached
~100% confluence, they were fixed with ethanol, labeled
with F-MuLV Env-specific MAb 720 [60], and then with
a horseradish peroxidase (HRP)-conjugated rabbit anti-
m o u s eI ga n t i b o d y( D a k o ,H a m b u r g ,G e r m a n y ) .T h e
assay was developed using aminoethylcarbazole (Sigma-
Aldrich, Deisenhofen, Germany) as substrate to detect
foci. Foci were counted, and focus-forming units (FFU)/
ml plasma were calculated.
Infectious center assay
21 days p.c. FV-infected animals were sacrificed by cervical
dislocation, the spleens were removed and weighed, and
single-cell suspensions were prepared. Serial dilutions of
isolated spleen cells were seeded onto M. dunni cells and
incubated under standard tissue culture conditions for 3
days, fixed with ethanol, and stained as described for the
viremia assay. Resulting foci were counted, and infectious
centers (IC)/spleen were calculated.
Binding antibody ELISA
For the analysis of F-MuLV-binding antibodies, Maxi-
Sorp ELISA plates (Nunc, Roskilde, Denmark) were
coated with whole F-MuLV antigen (5 μg/ml), blocked
with fetal calf serum, and incubated with serum dilu-
tions. Binding antibodies were detected using a polyclo-
nal rabbit-anti-mouse HRP-coupled anti-IgG antibody
and the substrate tetramethylbenzidine (TMB+; both
Dako Deutschland GmbH, Hamburg, Germany). Sera
were considered positive if the optical density at 450 nm
was 3-fold higher than that obtained with sera from
naïve mice.
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assay
To detect F-MuLV-neutralizing antibodies, serial dilutions
of plasma in PBS were mixed with purified F-MuLV and
guinea pig complement (Institut Virion/Serion GmbH,
Wuerzburg, Germany), incubated at 37°C for 60 min, and
then added to M. dunni cells that had been plated at a
density of 7.5 × 10
3 cells per well in 24-well plates the day
before. Seventy-two hours later cells were stained as
described for the viremia assay. Dilutions that resulted in a
reduction of foci by 50% or more were considered
neutralizing.
Tetramer staining of F-MuLV-specific T cells
Spleens of CB6F1 mice were removed 3 days post-
challenge (p.c.), and single-cell suspensions were pre-
pared. For analysis of CD4
+ T cells, spleen cells were
stained with a phycoerythrin (PE)-coupled major histo-
compatibility complex (MHC) class II tetramer (con-
taining the I-Ab-restricted F-MuLV Env epitope
EPLTSLTPRCNTAWNRLKL [22]; kindly provided by
the MHC Tetramer Core Facility of the National Insti-
tutes of Health, National Institute of Allergy and Infec-
tious Disease, Atlanta, GA), peridinin chlorophyll
protein (PerCP)-anti-CD4, and fluorescein isothiocya-
nate (FITC)-anti-CD11b (Becton Dickinson, Heidel-
berg, Germany). For detection of virus-specific CD8
+
T cells, spleen cells were stained with PE-coupled
MHC I tetramer (containingt h eH - 2 D br e s t r i c t e d
F-MuLV Gag-leader epitope AbuAbulLAbuLTVFL in
which cysteine residues of the original amino acid
sequence were replaced by amino-butyric acid to pre-
vent disulfide bonding [21]), allophycocyanin (APC)-
anti-CD8 and FITC-anti-CD43. Data were acquired on
a flow cytometer (FACSCalibur; Becton Dickinson,
Mountain View, CA) and analyzed using CellQuest Pro
(version 4.0.1; Becton Dickinson) and FlowJo (version
7.6; Tree Star, Ashland, OR) software.
Flow-cytometric analysis of T cell induction
To analyze the induction of T cells by the vaccine, mice
were immunized once by footpad injection with Ad5.env
and Ad5.gag vectors (1 × 10
9 VP each) and co-immunized
with 1 × 10
9 VP Ad5.IFNa4 or Ad5.GFP as a control. Ten
days later, the popliteal lymph nodes were isolated and
lymph node cells were analyzed by flow cytometry. For
analysis of the activation of CD4
+ cells, we used the anti-
bodies PE-anti-CD4 (Becton Dickinson), peridinin chloro-
phyll protein complex (PerCP)-anti-CD43 (BioLegend,
Fell, Germany), phycoerythrin-cyanin-7 (Pe-Cy7)-anti-
CD62L (eBioscience, Frankfurt, Germany), APC-anti-
CD44 (Becton Dickinson) and eFluor450-anti-CCR7
(eBioscience). Data were acquired on an LSR II flow
cytometer (Becton Dickinson) and analyzed using FlowJo
software (Tree Star).
Intracellular cytokine staining
HIV-specific T cells were characterized by intracellular
cytokine staining. Two weeks after immunization with
vectors encoding HIV Env and Gag-Pol, spleens were
removed and spleen cells were stimulated for 6 h in vitro
with HIV Env- or Gag-derived peptides (IHIGPGRAFYT,
gp120309-320 [61], AMQMLKETI p2465-73 [24]) or Gag-
derived peptides (SPEVIPMFSALSEGA, p24165-179,
PVGEIYKRWIILGLN, p24257-271 [25]; Metabion, Mar-
tinsried, Germany) representing described CD8
+ and
CD4
+ T cell epitopes, respectively. Cells were stained
with PE-anti-interferon gamma (IFN-g), APC-anti-inter-
leukin-2 (IL-2), FITC-anti-tumor necrosis factor alpha
(TNF-a) and either PerCP-anti-CD8 or PerCP-anti-CD4
(all from Becton Dickinson, Heidelberg, Germany) and
analyzed by flow cytometry.
Statistical analyses
Statistical analyses were performed using the software Sig-
maStat 3.1 (Systat Software GmbH, Erkrath, Germany),
testing with the Kruskal-Wallis one-way analysis of
variance on ranks and Student-Newman-Keuls multiple
comparison procedure.
Additional material
Additional file 1: Figure S1: Immunization schemes. This additional
file provides schematic layouts of the experiments, indicating treatment
and analysis schedules.
Additional file 2: Figure S2: Expression levels of type I interferons
in Ad-infected DCs. The intrinsic expression levels of the tested type I
interferons in DCs infected with Ad5.env were analyzed and compared
to uninfected DCs.
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